Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of oral atogepant for prevention of chronic or episodic migraine
2020-002470-27Phase 3Active
- Sponsor
- Allergan
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atogepant in migraine and chronic migraine, sponsored by Allergan. Primary endpoint: Long-term safety and tolerability of atogepant 60 mg once daily over 52 weeks. Started Mar 2021; status: active.
02
Drugs
atogepant
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on 2020-002470-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002470-27.